Iovance Biotherapeutics Inc

6. Nov. 2026, 20:52 UTC

Iovance Biotherapeutics stock advanced after Citizens raised its price target to $12 from $8, while Barclays increased its target to $19 from $18.

5. Nov. 2026, 23:03 UTC

Iovance Biotherapeutics Inc shares declined modestly in after-market trading, continuing a downward trend following three consecutive sessions of losses.

4. Nov. 2026, 23:06 UTC

Iovance Biotherapeutics Inc is seeing a slight decline in after-market trading, fluctuating between a low of -0.3% and a high of +0.5%.

3. Nov. 2026, 23:41 UTC

Iovance Biotherapeutics Inc shares are trading modestly lower in after-market hours, following a brief rise earlier in the session before a sharp retracement.

2. Nov. 2026, 20:52 UTC

Shares of Iovance Biotherapeutics Inc are declining, continuing a trend of weaker performance since Friday's close, despite an earlier session spike.

30. Okt. 2026, 20:04 UTC

Iovance Biotherapeutics' price target was lowered to $9.00 from $11.00 by Baird, contributing to the stock's decline amid concerns over a halted lung cancer trial.

29. Okt. 2026, 23:02 UTC

Iovance Biotherapeutics Inc shares are declining in after-market hours amid a broader market downturn influenced by mixed economic data and inflation concerns.

28. Okt. 2026, 23:06 UTC

Iovance Biotherapeutics to host a webcast on October 29, 2026, presenting positive data on lifileucel TIL therapy for metastatic non-small cell lung cancer.

27. Okt. 2026, 19:26 UTC

Iovance Biotherapeutics announced that its lifileucel monotherapy showed unprecedented efficacy in treating metastatic UPS and DDLPS at the ESMO Congress 2026.

26. Okt. 2026, 23:16 UTC

Iovance Biotherapeutics announced its lifileucel monotherapy showed unprecedented efficacy against metastatic UPS and DDLPS during a pilot trial at ESMO Congress 2026.

23. Okt. 2026, 20:07 UTC

Iovance Biotherapeutics presented new data at the ESMO Congress 2026, showing a 62.5% confirmed objective response rate for its lifileucel therapy in melanoma.

22. Okt. 2026, 23:06 UTC

Iovance Biotherapeutics Inc is experiencing a slight decline in after-market trading following Thursday's close, amid routine fluctuations and strong one-month performance.

19. Okt. 2026, 20:07 UTC

Iovance Biotherapeutics is presenting its TIL cell therapy platform at ESMO 2026, sharing five abstracts, including clinical data for lifileucel in advanced melanoma.

16. Okt. 2026, 20:02 UTC

Iovance Biotherapeutics Inc shares are declining, reversing from a recent trend of higher daily closes, amid a broader downward shift in momentum.

15. Okt. 2026, 20:07 UTC

Iovance Biotherapeutics Inc shares are trading higher, recovering from earlier weakness and gaining significantly since Wednesday's close.

14. Okt. 2026, 23:31 UTC

Iovance Biotherapeutics Inc shares are trading lower after the market closed, continuing a four-session decline amid broader market drops and rising Treasury yields.

13. Okt. 2026, 23:01 UTC

Iovance Biotherapeutics Inc is trading lower in after-market hours after peaking briefly post-session before retracing to a loss.

9. Okt. 2026, 20:01 UTC

Iovance Biotherapeutics Inc is trading sharply higher, continuing an upward trend since Thursday's close, with unusually high market volume today.

8. Okt. 2026, 19:26 UTC

Iovance Biotherapeutics shares advanced after Baird upgraded the price target to $11.00 from $6.00, citing recent developments in clinical programs and market positioning.

7. Okt. 2026, 23:05 UTC

Iovance Biotherapeutics Inc is trading lower in after-market hours, showing a cumulative decline since Wednesday's close despite strong gains in the biotechnology sector.

6. Okt. 2026, 20:02 UTC

Iovance Biotherapeutics Inc shares fell sharply, breaking a trend of higher daily closes, amid unusually high market volume during Tuesday's trading session.

30. Sept. 2026, 20:07 UTC

Iovance Biotherapeutics shares are advancing as Wells Fargo raises its price target to $18 and TD Cowen increases its target to $16, citing strong growth prospects.

29. Sept. 2026, 20:02 UTC

Iovance Biotherapeutics raised its 2026 revenue guidance to $410M-$420M, driven by strong product demand, as shares advance sharply to a new 52-week high.

24. Sept. 2026, 20:02 UTC

Iovance Biotherapeutics shares are sharply higher as Goldman Sachs reinstates a Buy rating with a $15.00 price target, projecting $1.2 billion in sales by 2037.

23. Sept. 2026, 20:07 UTC

Iovance Biotherapeutics Inc shares fell sharply amid significant volatility on Wednesday, continuing a decline that began since Tuesday's close.

22. Sept. 2026, 23:25 UTC

Iovance Biotherapeutics Inc is trading modestly higher in after-market hours, continuing a broader trend of significant gains over the past month.

21. Sept. 2026, 20:06 UTC

Iovance Biotherapeutics Inc shares fell sharply, pulling back from earlier session highs amid broader market trends that have seen declines today.

18. Sept. 2026, 23:41 UTC

Iovance Biotherapeutics granted inducement stock options for 179.75k shares to new employees, contributing to a modest decline in after-market hours.

17. Sept. 2026, 20:07 UTC

Barclays raised its price target on Iovance Biotherapeutics to $15, maintaining an Overweight rating amid positive survey results for Lifileucel ahead of the IOV-LUN-202 study update.

16. Sept. 2026, 19:03 UTC

Iovance Biotherapeutics reported record second-quarter revenue of nearly $100 million and is preparing for multiple data updates, driving shares higher since Tuesday.